Prolonged response to pembrolizumab in BRAFV600E microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden
The Oncologist · 08.05.2026 · 31 (6)
DOI: 10.1093/oncolo/oyag161 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Oncologist, online erschienen am 06.05.2026. Verfasst von Yu-Hsuen Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Gastrointestinal Unit, The Royal Marsden Hospital, London, SW3 6JJ, United Kingdom. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institute for Health Research (NIHR) Academic Clinical Fellowship (ACF), NIHR, NIHR Royal Marsden/Institute of Cancer Research (ICR) Biomedical Research Centre (BRC).
Abstract (Originalsprache)
BRAFV600E-mutant metastatic colorectal cancer (mCRC) is an aggressive molecular subtype associated with poor prognosis and relative chemoresistance. Outcomes following progression on chemotherapy and MAPK-targeted therapy with encorafenib plus cetuximab remain poor, highlighting an unmet need for effective later-line treatments. Immune checkpoint inhibitors have limited activity in microsatellite-stable (MSS) mCRC, and predictive biomarkers beyond mismatch repair deficiency remain poorly defined. We report a patient with BRAFV600E-mutant MSS mCRC who achieved a prolonged response to PD-1 blockade with pembrolizumab following a dynamic increase in tumor mutational burden (TMB). A 58-year-old woman initially responded to first-line chemotherapy but subsequently progressed on multiple treatment lines, including encorafenib plus cetuximab. Longitudinal genomic profiling using tumor tissue and circulating tumor DNA (ctDNA) revealed persistent BRAFV600E signaling with molecular evolution, including acquisition of a PIK3R1 variant associated with resistance to MAPK inhibition and emergence of TMB-high status. Fifth-line pembrolizumab produced a dramatic radiological response, with ongoing disease control more than 2 years later. We discuss the mechanistic framework by which a subset of BRAFV600E-mutant MSS mCRC may respond to immune checkpoint inhibition through an inflamed immune microenvironment driven by constitutive MAPK signaling. This case illustrates the interplay between tumor-agnostic biomarkers such as TMB-high and tumor-specific context, and highlights the value of longitudinal genomic profiling, including ctDNA, to identify resistance mechanisms and guide treatment selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Gastrointestinal Unit, The Royal Marsden Hospital, London, SW3 6JJ, United Kingdom.
ORCID-Profile: Yu-Hsuen Yang, Naureen Starling
Förderung
- National Institute for Health Research (NIHR) Academic Clinical Fellowship (ACF)
- NIHR
- NIHR Royal Marsden/Institute of Cancer Research (ICR) Biomedical Research Centre (BRC)
Zitieren
APA
Yang, Y. H., Starling, N., & Cartwright, E. (2026). Prolonged response to pembrolizumab in BRAFV600E microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag161
Vancouver
Yang YH, Starling N, Cartwright E. Prolonged response to pembrolizumab in BRAFV600E microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag161
BibTeX
@article{Yang2026,
author = {Yang, Yu-Hsuen and Starling, Naureen and Cartwright, Elizabeth},
title = {Prolonged response to pembrolizumab in BRAFV600E microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {6},
doi = {10.1093/oncolo/oyag161}
}
EUVIMED